BUZZ-抗炎药物在中期研究中获得成功后，Roivant 公司业绩大增

Reuters04-02

((自动化翻译由路透提供，请见免责声明 ))

4月2日 - ** Roivant Sciences 股价在盘前交易中上涨7.4%，报11.20美元

** 该公司称其治疗非传染性葡萄膜炎的试验性药物在一项中期研究中有助于减轻炎症性眼病的症状 (link)

** 在对26名患者进行的测试研究中，接受较高强度45毫克(mg) 剂量治疗的患者中有29%出现治疗失败，而接受15毫克剂量治疗的患者中有44%出现治疗失败，较低的治疗失败率意味着该药物的益处更大。

** 布雷博西替尼这种药物还有助于减轻一些接受高剂量治疗的患者的黄斑水肿。

** 截至上一交易日收盘，股价年累计下跌约 7

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2424019130?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-02 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424019130","market":"us","top_or_hot":-1,"title":"BUZZ-抗炎药物在中期研究中获得成功后，Roivant 公司业绩大增","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    4月2日 - ** Roivant Sciences   股价在盘前交易中上涨7.4%，报11.20美元 </p><p>** 该公司称其治疗非传染性葡萄膜炎的试验性药物在一项中期研究中有助于减轻炎症性眼病的症状 (link) </p><p>** 在对26名患者进行的测试研究中，接受较高强度45毫克(mg) 剂量治疗的患者中有29%出现治疗失败，而接受15毫克剂量治疗的患者中有44%出现治疗失败，较低的治疗失败率意味着该药物的益处更大。</p><p>** 布雷博西替尼这种药物还有助于减轻一些接受高剂量治疗的患者的黄斑水肿。</p><p>** 截至上一交易日收盘，股价年累计下跌约 7  </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-抗炎药物在中期研究中获得成功后，Roivant 公司业绩大增</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-抗炎药物在中期研究中获得成功后，Roivant 公司业绩大增\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-02 20:08 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    4月2日 - ** Roivant Sciences   股价在盘前交易中上涨7.4%，报11.20美元 ** 该公司称其治疗非传染性葡萄膜炎的试验性药物在一项中期研究中有助于减轻炎症性眼病的症状 (link) ** 在对26名患者进行的测试研究中，接受较高强度45毫克(mg) 剂量治疗的患者中有29%出现治疗失败，而接受15毫克剂量治疗的患者...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BUZZ","symbol_name":"VanEck Social Sentiment ETF","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424019130","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424019130","pubTimestamp":1712059733,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自动化翻译由路透提供，请见免责声明 ))    4月2日 - ** Roivant Sciences   股价在盘前交易中上涨7.4%，报11.20美元 ** 该公司称其治疗非传染性葡萄膜炎的试验性药物在一项中期研究中有助于减轻炎症性眼病的症状 (link) ** 在对26名患者进行的测试研究中，接受较高强度45毫克(mg) 剂量治疗的患者中有29%出现治疗失败，而接受15毫克剂量治疗的患者中有44%出现治疗失败，较低的治疗失败率意味着该药物的益处更大。** 布雷博西替尼这种药物还有助于减轻一些接受高剂量治疗的患者的黄斑水肿。** 截至上一交易日收盘，股价年累计下跌约 7","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BUZZ":"VanEck Social Sentiment ETF","BK4007":"制药","ROIV":"Roivant Sciences Ltd.","BK4139":"生物科技"},"translate_title":"Roivant's performance increased greatly after the success of BUZZ-anti-inflammatory drug in mid-term research","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"ROIV":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    4月2日 - ** Roivant Sciences   股价在盘前交易中上涨7.4%，报11.20美元 ** 该公司称其治疗非传染性葡萄膜炎的试验性药物在一项中期研究中有助于减轻炎症性眼病的症状 (link) ** 在对26名患者进行的测试研究中，接受较高强度45毫克(mg) 剂量治疗的患者中有29%出现治疗失败，而接受15毫克剂量治疗的患者中有44%出现治疗失败，较低的治疗失败率意味着该药物的益处更大。** 布雷博西替尼这种药物还有助于减轻一些接受高剂量治疗的患者的黄斑水肿。** 截至上一交易日收盘，股价年累计下跌约 7","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424019130"}